Risk factor
Weak & very vulnerable to price shocks
Profitability factor
Very strong margins and returns
About
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to...
Company Valuation
Based on key historical and expected multiples, the stock is undervalued relative to its peers. In particular, the stock is underpriced on P/E, 'cheap' on EV/EBITDA, unde
Target Price
The average target price of HRMY is 44 and suggests 53% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increase
Buy
Sell